Alaunos Therapeutics, Inc. (TCRT): Nasdaq/NYSE listing notice — Alaunos receives Nasdaq deficiency notice for equity below $2.5M minimum; 45 days to submit plan

Alaunos Therapeutics, Inc.

Stockholders' equity of $2.063M as of Dec 31, 2024, falls short of Nasdaq's $2.5M minimum under Rule 5550(b)(1).
Company has 45 days from Apr 7, 2025 to submit a compliance plan; if accepted, may have up to 180 days to cure.
Nasdaq also removed the one-year Panel Monitor that had been in place since February 2024.
The deficiency notice does not immediately affect listing, but non-compliance could lead to delisting.
Company intends to evaluate options and submit a plan to regain compliance within the allowed timeframe.

item 3.01 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Alaunos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 7, 2025, Alaunos Therapeutics, Inc., (the “Company”) received a notice (the “Notice”) from the Listing Qualifications staff of Nasdaq notifying the Company that the Company’s stockholders equity as reported in its Annual Report on Form 10-K for the period ended December 31, 2024 (the “2024 10-K”), did not satisfy the continued listing requirements under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholder equity be at least $2,500,000. In its 2024 10-K, the Company reported stockholders’ equity of $2,063,000, and, as a result, d

View on SEC.gov

Browse all listing & compliance notices →

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-053325

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.